ReviewCancer cell international2025
Deciphering 17-β-hydroxysteroid dehydrogenase 4: from molecular insights to cancer therapeutics.
Review in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Genetic parameters of feeding behavior traits and multi-tissue transcriptomic comparison of divergent feeding patterns in ducks.Poultry science · 2026Article
- Molecular regulatory network of glycolytic reprogramming in hepatocellular carcinoma and its clinical implications.Biological procedures online · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
17-β-hydroxysteroid dehydrogenase 4 (HSD17B4), abundantly present in the peroxisomal regions of mammalian cells, is an oxidoreductase that catalyzes the oxidoreduction of steroid substrates. Impairment of lipid metabolism represents one of the most critical metabolic alterations in cancer, with lipid metabolic processes tightly linked to tumor cell proliferation, survival, invasion, and metastasis. HSD17B4 is primarily involved in the regulation of cellular fatty acid and hormone metabolism. Therefore, HSD17B4 is closely related to tumors, but few relevant studies exist. Polymorphisms and methylation of the HSD17B4 gene, as well as acetylation of the HSD17B4 protein, influence its expression and function, impacting cancer progression and therapeutic response. Recent findings also highlight HSD17B4 as a potential therapeutic target and prognostic biomarker in various cancers. Here, we will discuss the latest literature on human HSD17B4 and its clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.